Potential Biomarkers in Atrial Fibrillation: Insight Into Their Clinical Significance

Simple item page
dc.contributor.authorCharafeddine, Khalil M.
dc.contributor.authorZakka, Patrick K.
dc.contributor.authorDargham, Bassel Bou
dc.contributor.authorAbdulhai, Farah A.
dc.contributor.authorZakka, Katerina Mary
dc.contributor.authorZouein, Fouad A.
dc.contributor.authorRefaat, Marwan M.
dc.contributor.departmentPathology and Laboratory Medicine
dc.contributor.departmentInternal Medicine
dc.contributor.departmentPharmacology and Toxicology
dc.contributor.departmentDivision of Cardiology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:10:09Z
dc.date.available2025-01-24T12:10:09Z
dc.date.issued2021
dc.description.abstractIn risk-stratifying patients with atrial fibrillation (AF), physicians rely heavily on clinical parameters that provide risk scores and determine treatment strategies. There has been increasing research on potential biomarkers in the blood that could more accurately determine both risk of complications in AF and risk of incidence of AF. This review highlights the clinical significance of 5 novel biomarkers that have been shown to be linked to AF. These biomarkers are carbohydrate antigen 125, galectin-3, growth differentiation factor-15, a member of the interleukin 1 receptor family, IL1RL1 (ST2), and N-terminal pro B-type natriuretic peptide. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
dc.identifier.doihttps://doi.org/10.1097/FJC.0000000000001042
dc.identifier.eid2-s2.0-85117433944
dc.identifier.pmid34173807
dc.identifier.urihttp://hdl.handle.net/10938/32266
dc.language.isoen
dc.publisherLippincott Williams and Wilkins
dc.relation.ispartofJournal of Cardiovascular Pharmacology
dc.sourceScopus
dc.subjectAtrial fibrillation
dc.subjectBiomarker
dc.subjectCarbohydrate antigen 125
dc.subjectGalectin-3
dc.subjectGrowth differentiation factor-15
dc.subjectN-terminal pro b-type natriuretic peptide
dc.subjectSuppression of tumorigenicity 2
dc.subjectAction potentials
dc.subjectAnimals
dc.subjectAtrial function
dc.subjectBiomarkers
dc.subjectBlood proteins
dc.subjectCa-125 antigen
dc.subjectClinical decision-making
dc.subjectGalectins
dc.subjectGrowth differentiation factor 15
dc.subjectHeart atria
dc.subjectHeart rate
dc.subjectHumans
dc.subjectMembrane proteins
dc.subjectNatriuretic peptide, brain
dc.subjectPeptide fragments
dc.subjectPredictive value of tests
dc.subjectPrognosis
dc.subjectReceptors, interleukin-1 type i
dc.subjectBiological marker
dc.subjectBrain natriuretic peptide
dc.subjectCa 125 antigen
dc.subjectGalectin
dc.subjectGdf15 protein, human
dc.subjectIl1r1 protein, human
dc.subjectInterleukin 1 receptor type i
dc.subjectLgals3 protein, human
dc.subjectMembrane protein
dc.subjectMuc16 protein, human
dc.subjectPeptide fragment
dc.subjectPlasma protein
dc.subjectPro-brain natriuretic peptide (1-76)
dc.subjectAction potential
dc.subjectAnimal
dc.subjectBlood
dc.subjectClinical decision making
dc.subjectHeart atrium
dc.subjectHeart atrium function
dc.subjectHuman
dc.subjectMetabolism
dc.subjectPathophysiology
dc.subjectPredictive value
dc.titlePotential Biomarkers in Atrial Fibrillation: Insight Into Their Clinical Significance
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2021-2464.pdf
Size:
121.34 KB
Format:
Adobe Portable Document Format
Download

Collections

Pathology and Laboratory Medicine
Internal Medicine
Pharmacology and Toxicology